(Q36577380)

15 August 2017

1 reference

title

The management of pediatric systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

15 August 2017

main subject

0 references

author name string

Stacy P Ardoin

series ordinal

1

1 reference

15 August 2017

Laura E Schanberg

series ordinal

2

1 reference

15 August 2017

publication date

1 December 2005

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

82-92

1 reference

The epidemiology of systemic lupus erythematosus

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Lupus nephritis in childhood: a review of 53 patients followed at a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Childhood-onset Systemic Lupus Erythematosus: clinical presentation and prognosis in 31 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Intermittent intravenous cyclophosphamide therapy for lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Safety of GnRH agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Premature coronary-artery atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Immunisation of patients with systemic lupus erythematosus: the current state of play

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Influenza vaccination in patients with rheumatic diseases. Safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Long-term treatment of systemic lupus erythematosus with cyclosporin A

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Haematopoietic stem cell transplantation for active systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Dyslipoproteinemia in pediatric systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Antigen-specific antibody responses in lupus patients following immunization

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Transition of the Adolescent Patient with Rheumatic Disease: Issues to Consider

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0046

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0046

1 reference

15 August 2017

1 reference